Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 8, 2020

Primary Completion Date

February 13, 2021

Study Completion Date

February 13, 2021

Conditions

Covid19

Interventions

DRUG

BGB DXP593

Administered intravenously (IV) as specified in the treatment arm

DRUG

Placebo

Placebo to match BGB-DXP593

Trial Locations (1)

Q PHARM, Herston